BOSTON ONCOLOGY ARABIA and SPIMACO have signed a Memorandum of Understanding (MoU) to localize the production of advanced oral oncology treatments in the Kingdom. This partnership reflects a shared commitment to improving patient outcomes, fostering local expertise, and contributing to Saudi Arabia’s Vision 2030 goals for healthcare transformation.
Read also – Sumitomo Mitsui Auto Service acquires stake in Tribecar
The partnership, which is centered on knowledge and technology transfer, will allow the parties to locally market vital oral oncology drugs. In addition to increasing access to life-saving therapies, the project fortifies the Kingdom’s healthcare and industrial sectors. Saudi Arabia’s dominance in the regional and international pharmaceutical markets is strengthened by this partnership.
Read also – Second Cohort of MIT DesignX Dubai Accelerator
The agreement supports Vision 2030’s objectives to boost local industry, decrease reliance on imports, and improve patient access to cutting-edge medicines for patients throughout the Kingdom by establishing local manufacturing capabilities for advanced oral oncology medications.
“This agreement marks a significant milestone toward ensuring that patients in Saudi Arabia and beyond have access to world-class oncology treatments without delay,” said Dr. Abdullah Baaj, CEO of Boston Oncology Arabia. “By localizing production and investing in cutting-edge technologies, we are not just meeting immediate needs—we are modeling a sustainable future for oncology care in the GCC / MENA region.”
SPIMACO CEO Jérôme Cabannes added: “This partnership enhances our ability to provide high-quality oncology treatments and strengthens our commitment to the Kingdom’s vision of a self-reliant healthcare system. It reflects our shared dedication to patient care and reinforces our leadership role in the pharmaceutical industry.”
Over the next five years, the collaboration will give top priority to the commercialization of important oral oncology treatments, which will have a major positive impact on the creation of jobs, the growth of local knowledge and production capabilities, and the fair distribution of essential cancer treatments throughout Saudi Arabia and the larger MENA area.
This agreement exemplifies how audacious strategic alliances can open up new avenues for improving oncology care and meeting pressing medical demands.
About Boston Oncology Arabia
Boston Oncology Arabia exemplifies the value and effectiveness of the Boston Oncology model. Boston Oncology laid a foundation to become the leading local provider of specialty biogenerics in Saudi Arabia. Boston Oncology Arabia is under contract for 3 years as a preferred supplier to King Faisal Specialist Hospital, and has sold to 15 government hospitals.
